美国癌症研究协会（AACR）年会是全球历史悠久、肿瘤领域最具影响力的学术盛会之一。会议关注高质量肿瘤研究及创新研究，聚焦肿瘤领域热点，汇集最前沿进展和科研成果。
第115届AACR年会将于美国东部时间2024年4月5~10日在美国举行。当地时间3月5日AACR官网公布了标题，【肿瘤资讯】为您精选出消化道肿瘤领域相关重要临床研究进展。
Late-Breaking Poster Session
LBPO.CL01. Late-Breaking Research: Clinical Research 1
摘要号：LB090/1
摘要标题：Predictive genomic biomarkers for atezolizumab plus bevacizumab combination immunotherapy response in liver cancer: Insights from the IMbrave150 trial
中文标题：预测阿替利珠单抗联合贝伐珠单抗免疫治疗肝癌疗效的基因组生物标志物（IMbrave150研究）
讲者：J.-S. Lee（MD安德森癌症中心）
摘要号：LB103/14
摘要标题：Cell-free DNA methylation as a noninvasive prognostic biomarker in hepatocellular carcinoma
中文标题：cfDNA甲基化作为肝细胞癌（HCC）无创性预后生物标志物的研究进展
讲者：R. Hu（加州大学洛杉矶分校）
摘要号：LB109/20
摘要标题：Detection of high grade intraepithelial neoplasia in colorectal cancer using a new blood-based multiplex septin9 methylation assay
中文标题：血液多重septin9甲基化检测技术在CRC高级别上皮内瘤变中的检测价值
讲者：D. Yu（广西右江民族医学院）
LBPO.CL02. Late-Breaking Research: Clinical Research 2
摘要号：LB330/4
摘要标题：CWH43 as a prognostic marker and therapeutic target in colorectal cancer
中文标题：CWH43作为CRC预后标志物和治疗靶点
讲者：C.-C. Lee（中国台北医学大学）
摘要号：LB349/23
摘要标题：Cysteine restriction enhances antitumor immunity in colorectal cancer
中文标题：半胱氨酸限制增强CRC的抗肿瘤免疫
讲者：J. Li（北京大学第一医院）
Clinical Trials Plenary Session
CTPL02 - Novel Immune Checkpoint Inhibitor Combinations
摘要号：CT006
摘要标题：Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial
中文标题：卡度尼利单抗联合化疗对比化疗一线治疗不可切除局部晚期或转移性胃/胃食管结合部腺癌的随机、双盲、3期试验（COMPASSION-15）
讲者：季加孚教授（北京大学肿瘤医院）
摘要号：CT007
摘要标题：Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)
中文标题：Copanlisib联合纳武利尤单抗治疗微卫星稳定（MSS）结直肠癌（CRC）的1/2期试验
讲者：E. S. Christenson（约翰·霍普金斯医院）
CTPL03 - Advances in Targeted Therapy
摘要号：CT013
摘要标题：KRYSTAL-1: Pooled phase 1/2 efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRASG12C mutation
中文标题：adagrasib（MRTX849）联合西妥昔单抗治疗KRAS G12C突变mCRC患者的疗效和安全性（KRYSTAL-1研究）
讲者：S. Kopetz（MD安德森癌症中心）
CTPL04 - Biomarkers: Quantifying Pharmacodynamic Modulation
摘要号：CT016
摘要标题：Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of entinostat in combination with nivolumab
中文标题：HDACi对胰腺导管腺癌肿瘤微环境的免疫调节作用：entinostat联合纳武利尤单抗的2期临床试验结果
讲者：M. Baretti（约翰霍普金斯大学医学院）
Clinical Trials Minisymposium
CTMS01 - Cancer Vaccines: Ready for Prime Time?
摘要号：CT022
摘要标题：Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study
中文标题：基于突变KRAS多肽的疫苗在高危胰腺癌患者中的初步应用
讲者：S. D. Haldar（约翰霍普金斯大学医学院）
摘要号：CT134
摘要标题：Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma
中文标题：胰腺癌新辅助/辅助治疗中，分泌GM-CSF的同种异体胰腺肿瘤细胞疫苗(GVAX)联合环磷酰胺、帕博利珠单抗和巨噬细胞靶向CSF1R抑制剂IMC-CS4的安全性及免疫学影响
讲者：A.Urman（约翰霍普金斯大学医学院）
CTMS02 - Advances in Immunotherapy
摘要号：CT031
摘要标题：A pilot clinical trial of neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer
中文标题：改良FOLFIRINOX联合纳武利尤单抗新辅助治疗临界可切除胰腺癌的初步临床试验
讲者：Z. A. Wainberg（加州大学洛杉矶分校医学中心）
CTMS03 - Novel Agents and Emerging Therapeutic Strategies
摘要号：CT038
摘要标题：Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study
中文标题：抗TROP2 ADC SKB264 (MK-2870)在既往治疗过的进展期胃癌/胃食管结合部癌症患者中的初步疗效和安全性结果：来自一项2期研究
讲者：J. Rodon（MD安德森癌症中心）
Clinical Trial Poster Sessions
PO.CTP01.01 - Phase I Clinical Trials in Progress 1
摘要号：CT080/7
摘要标题：A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma
中文标题：CPI-613（devimistat）联合放化疗治疗胰腺导管腺癌的I期临床研究
讲者：M. Kamgar（Wisconsin大学医学院）
摘要号：CT083/10
摘要标题：A first-in-human phase 1/2a study of a novel anti-PAUF monoclonal antibody PBP1510 in patients with advanced/metastatic pancreatic cancer
中文标题：新型抗PAUF单克隆抗体PBP1510用于晚期/转移性胰腺癌患者的首次人体1/2a期研究
讲者：J. Kim（新加坡）
摘要号：CT090/17
摘要标题：DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas
中文标题：DAREON™-7：BI 764532联合含铂化疗药物一线治疗DLL3阳性(+)神经内分泌癌患者的1期、开放标签、剂量递增和扩展队列试验
讲者：P. Sun（勃林格殷格翰）
PO.CT02.01 - Phase II Clinical Trials 1
摘要号：CT209/9
摘要标题：Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial
中文标题：卡瑞利珠单抗联合化疗新辅助治疗可切除局部晚期食管鳞癌（LA-ESCC）一项单中心、随机、II期试验
讲者：F. Dong（北京大学肿瘤医院）
摘要号：CT210/10
摘要标题：Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
中文标题：索拉非尼联合帕博利珠单抗治疗晚期肝细胞癌（HCC）的Ib/II期研究
讲者：R. Iyer（Roswell Park综合癌症中心）
摘要号：CT212/12
摘要标题：Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC
中文标题：阿替利珠单抗+etrumadenant+化疗 vs 单纯化疗治疗PDAC的全球、开放标签、随机Ib/II期研究（MORPHEUS-PDAC）
讲者：K.-P. Kim（韩国）
摘要号：CT213/13
摘要标题：Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
中文标题：安罗替尼联合化疗一线治疗不可切除肝转移胃肠道肿瘤患者：来自多队列、多中心II期试验ALTER-G-001-队列C的最新结果
讲者：吴珺玮（上海交通大学医学院附属瑞金医院）
摘要号：CT214/14
摘要标题：Paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL)
中文标题：Paricalcitol联合化疗用于未经治疗的转移性胰腺导管腺癌（PINBALL）
讲者：D. Propper（Barts & The London NHS Trust，英国伦敦）
摘要号：CT215/15
摘要标题：Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma - Final results from Phase II/HERIZON study
中文标题：IMU-131联合标准化疗治疗HER2+转移性/晚期G/GEJ腺癌患者的OS（II期HERIZON研究的最终结果）
讲者：J. Tobias（奥地利Vienna医科大学）
摘要号：CT216/16
摘要标题：Anti-EGFR in combination with paclitaxel as second-line therapy for gastric cancer with EGFR overexpression
中文标题：抗EGFR联合紫杉醇二线治疗EGFR过表达胃癌
讲者：H. K. Kim（韩国国立癌症中心）
摘要号：CT217/17
摘要标题：First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial
中文标题：度伐利尤单抗+曲美木单抗+化疗一线治疗RAS突变mCRC：一项1b/2期临床试验
讲者：M. Thibaudin（法国Centre Georges Francois Leclerc）
摘要号：CT218/18
摘要标题：Phase II open label trial of Minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer
中文标题：Minnelide™治疗化疗难治性转移性胰腺癌的开放标签II期试验
讲者：D. Propper（英国伦敦Barts Cancer Institute）
摘要号：CT220/20
摘要标题：Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis
中文标题：narmafotinib（AMP945）联合吉西他滨和Abraxane一线治疗晚期胰腺癌患者的1b/2a期试验（ACCENT试验）的中期分析
讲者：T.-A. Cock（澳大利亚Amplia Therapeutics）
PO.CT02.02 - Phase II Clinical Trials 2
摘要号：CT266/25
摘要标题：Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 study
中文标题：索凡替尼（surufatinib）联合信迪利单抗和IBI310治疗高级别晚期神经内分泌瘤的初步疗效：一项多中心、单臂2期研究
讲者：P. Zhang（北京大学肿瘤医院）
PO.CTP02.01 - Phase II and Phase III Clinical Trials in Progress
摘要号：CT275/5
摘要标题：A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)
中文标题：onvansertib联合标准治疗（SoC）与单独SoC一线治疗RAS突变转移性结直肠癌（mCRC）的2期随机、开放标签研究
讲者：R. A. Subramanian（Cardiff Oncology公司）
摘要号：CT276/6
摘要标题：Liberty-201: Maintenance fluoropyrimidine and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)
中文标题：Liberty-201：氟嘧啶和贝伐珠单抗联合/不联合抗LAG-3抗体LBL-007和抗PD-1抗体替雷利珠单抗用于转移性/不可切除MSS/pMMR CRC患者的维持治疗
讲者：Heinz-Josef Lenz（南加州大学/诺里斯综合癌症中心）
如有错误之处，敬请指正！
排版编辑：Marie
苏公网安备32059002004080号
